Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kerato Conjunctivitis Sicca Clear all
Completed No phase listed Observational

Patient Reported Outcomes With LASIK: PROWL-2

NCT01655420
View directory record Official record
Conditions
Laser in Situ Keratomileusis
Interventions
LASIK
Procedure
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
21 Years to 84 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Stanford, California • Indianapolis, Indiana • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Effect of Cequa™ in Subjects With Dry Eye Disease

NCT04357795
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solution
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Fort Myers, Florida • Jacksonville, Florida • Panama City, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

NCT04391894
View directory record Official record
Conditions
Dry Eye
Interventions
ECF843, ECF843 vehicle
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142
View directory record Official record
Conditions
Sjogren Disease
Interventions
Sibeprenlimab, Placebo
Biological · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Riverside, California • Tujunga, California • Brandon, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

NCT01817582
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Lotemax, Restasis, Soothe® Lubricant Eye Drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease

NCT00848198
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Not listed
Lead sponsor
TearLab Corporation
Industry
Eligibility
18 Years to 79 Years
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
San Diego, California • Louisville, Kentucky • Chesterfield, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dry Eye Assessment and Management: Feasibility Study

NCT01102257
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Omega-3 EFA Supplement, Olive Oil
Drug
Lead sponsor
Asbell, Penny, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02254265
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions
OTX-101 0.05%, OTX-101 0.09%, Vehicle
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

NCT04649177
View directory record Official record
Conditions
Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Ocular surface optical coherence tomography
Device
Lead sponsor
Boston Sight
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

NCT01900249
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Artesia, California • Petaluma, California • Rancho Cardova, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Jul 22, 2026, 5:59 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Examining the Immunological Process of Autoimmune Patients

NCT02123147
View directory record Official record
Conditions
Sjogren's Syndrome, Autoimmune Diseases, Dry Eyes, Dry Mouth
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Phase 4 Interventional Results available

A Study Evaluating the Safety of the Nasal Pump

NCT06329687
View directory record Official record
Conditions
Dry Eye, Kerato Conjunctivitis Sicca
Interventions
Tyrvaya Nasal Pump
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Not listed Phase 4 Interventional

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

NCT04863742
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

NCT00345241
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Systane Ocular Drops (OTC), Placebo - Saline Drops
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2008 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT02665234
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes

NCT03334539
View directory record Official record
Conditions
Dry Eye
Interventions
HL036 ophthalmic solution, Placebo vehicle solution
Biological · Other
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

NCT02819284
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

DNase Treatment for Dry Eyes

NCT02193490
View directory record Official record
Conditions
Dry Eye
Interventions
DNase, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye

NCT00883649
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Hydroeye, Inactive Capsule
Dietary Supplement · Other
Lead sponsor
Virginia Eye Consultants
Other
Eligibility
40 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2012 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

NCT04819269
View directory record Official record
Conditions
Dry Eye Disease, Sjögren Syndrome
Interventions
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 22, 2026, 5:59 AM EDT
Completed No phase listed Observational

Helicobacter Pylori and Dry Eye

NCT00083291
View directory record Official record
Conditions
Helicobacter Infections
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:59 AM EDT
Completed No phase listed Observational Results available

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

NCT00717418
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine ophthalmic emulsion 0.05%, artificial tears
Drug
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Wilson, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study Designed to Evaluate Tear Production

NCT06544707
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Ocular Surface Dry Eye Microbiome

NCT02306668
View directory record Official record
Conditions
Dry Eyes
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Jul 22, 2026, 5:59 AM EDT